Achieve Life
ACHV
7.24
+0.21
+2.99%
Achieve Life
US · ACHV
#3471 by market cap
7.24
+0.21
+2.99%
Live - 5344 symbols - heartbeat 552s ago
· 2026-10-08 09:06
Pre-market
7.19
-0.69%
After-hours
7.32
+1.10%
Overnight
7.27
+0.41%
- Market cap
- 746.46M
- P/E (TTM)i
- -4.36
- P/Bi
- -50.99
- EPSi
- -1.25
- Div yieldi
- 0.00%
- 52W posi
- 77%
Reader sentiment
Are you bullish or bearish on ACHV?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 85.56% +0.06pp
- Institutions
- 131 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund35.22%
VC/PE Fund25.18%
Hedge Fund23.30%
Individual/Insider2.31%
Public Company1.09%
Private Company0.47%
Insurance Company0.17%
Other12.12%
Top holders as of 2026-06-30
Frazier Life Sciences Management, LP
7.40% · 7.61M sh
TPG Capital, L.P.
6.68% · 6.88M sh
venBio LLC
5.75% · 5.91M sh
Logos Global Management, L.P.
5.27% · 5.43M sh
BlackRock
5.12% · 5.27M sh
Franklin Resources
4.81% · 4.95M sh
Paradigm Biocapital Advisors LP
4.81% · 4.95M sh
Vanguard Capital Management, LLC
4.60% · 4.73M sh
Propel Bio Management, LLC
3.92% · 4.03M sh
Marshall Wace LLP
3.66% · 3.77M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 9 sells
| Name | Role | Stake |
|---|---|---|
| Thomas King | Director | 0.31% |
| Richard A. Stewart | Executive Chairperson | 0.20% |
| Mark Oki | Chief Financial Officer | 0.12% |
| Jaime Xinos | Executive Vice President of Commercial | 0.07% |
| Craig Donnelly | Executive Vice President of CMC & Regulatory CMC | 0.05% |
| Mark Rubinstein | Head of Medical Affairs | 0.04% |
| Jerry Wan | Principal Accounting Officer | 0.03% |
| James Coulter | -- | -- |
| Cindy Jacobs | President, Chief Medical Officer & Director | -- |
| Stuart Duty | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-04 | Benjamin Halladay | Chief Financial Officer | Other Derivative Acquisition | +200,000 | $7.01 |
| 2026-08-18 | Richard A. Stewart | Executive Chairperson | Open Market Disposition | -20,626 | $8.49 |
| 2026-07-26 | Richard A. Stewart | Executive Chairperson | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Richard A. Stewart | Executive Chairperson | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Jeffrey S. Farrow | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Jeffrey S. Farrow | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Aaron Royston | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Aaron Royston | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Thomas Sellig | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Thomas Sellig | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Nancy Phelan | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Nancy Phelan | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Reid Waldman | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Reid Waldman | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Christopher Martin | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Christopher Martin | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-05-28 | Jeffrey S. Farrow | Director | Other Derivative Acquisition | +47,250 | $5.24 |
| 2026-05-28 | Reid Waldman | Director | Other Derivative Acquisition | +47,250 | $5.24 |
| 2026-05-10 | Christopher Martin | Director | Other Derivative Acquisition | +47,250 | $5.59 |
| 2026-04-17 | Andrew Goldberg | Chief Executive Officer | Other Derivative Acquisition | +1,800,965 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:06:46 · For reference only, not investment advice and not tailored to your situation.